News
Archives
- 2017
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2016
- Oct (1)
- Apr (2)
- Jan (1)
- 2015
- 2014
- 2013
- Oct (1)
- Jul (1)
-
Apr (5)
- First investigator meeting for our new North Asia sites for the first time
- The National Cancer Institute (U.S) has recently labelled Aspirin in Colorectal Cancer as one of the most provocative questions in cancer
- We congratulate Dr Tham and team, and team from Sixth Affiliated Hospital
- Zhejiang and Zhongshan hospitals obtained IRB approval
- PIK3CA subgroup analysis included as a new secondary endpoint
- Jan (2)
- 2012
- Oct (2)
- Apr (1)
- Jan (1)
- 2011
- Oct (1)
- Jul (1)
- Apr (1)
9 Jan 2013
ASCOLT Data and Safety Monitoring Committee first meeting
Our independent ASCOLT Data and Safety Monitoring Committee had their first meeting in December 2012, and we are pleased to report that they did not find a significant difference in adverse events between the two arms of the trial. The incidence of adverse events was considered to be appropriate for participants undergoing treatment for CRC. The DSMC did however stress the need to promptly report all deaths and SAEs on the study within the timeframe stipulated (within 24 hrs of 1st knowledge of event).